Other languages FibroGen, Inc.

Equities

FGEN

US31572Q8087

Delayed Nasdaq Other stock markets 15:52:21 2024-04-29 EDT			5-day change	1st Jan Change
1.08 ^USD	+3.85%		-5.26%	+21.85%

04-24	FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	CI
04-15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	04-24
Faron Pharmaceuticals reappoints former finance chief on interim basis	04-15
Top Midday Decliners	04-03
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	04-03
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	04-02
Sector Update: Health Care Stocks Rise Late Afternoon	03-12
Sector Update: Health Care Stocks Higher in Afternoon Trading	03-12
FibroGen Shares Jump After CEO Stock Purchase	03-12
FibroGen Names Deyaa Adib Chief Medical Officer	03-11
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	03-11
FibroGen regains rights to anemia drug from AstraZeneca	02-26
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea	02-26
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network?s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer	01-25
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06
FibroGen, Inc. Appoints Thane Wettig as a Member of the Board	23-10-06
FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer	23-10-06
Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023	23-09-06
Sector Update: Health Care Stocks Mixed Premarket Wednesday	23-08-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages FibroGen, Inc.

Equities

FGEN

US31572Q8087

Other languages

Filters